Imbalances in glycemic control, blood pressure, and diuretic use between treatment and placebo arms could have biased the cardiovascular and renal outcomes of recent large trials in favor of the study drugs for treating type 2 diabetes, some experts assert.
The cardiovascular outcomes trials (CVOTs) were mandated by the US Food and Drug Administration in 2008 to ensure the safety of newer agents being developed for type 2 diabetes following the debacle of rosiglitazone.
Results from some of the CVOTs and other subsequent dedicated trials showing cardiovascular and renal benefits have influenced clinical guidelines for type 2 diabetes and led to FDA approval of additional indications for some of the drugs beyond glucose lowering.
In nearly all these manufacturer-funded trials of a number of drug classes dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors glycemia and blood pressure were not strictly controlled but were left to the discretion of the treating physician, although some studies did include "rescue criteria."
Now in an article recently published online in the Journal of Pharmaceutical Policy and Practice, Japanese researchers Rumiko Shimazawa, PhD, of the Department of Clinical Pharmacology at Tokai University School of Medicine, and Masayuki Ikeda, MD, point out that A1c levels were significantly higher in placebo groups than in treatment groups in all of the CVOTs.
Those imbalances, they argue, placed patients in the placebo groups at potentially higher cardiovascular risk and thereby biased the results in favor of the study drug.
"Reanalysis with adjustment for the [A1c] imbalance is absolutely indispensable for the correct evaluation of the CVOTs," Ikeda, of the Department of Medical Informatics at Kagawa University Hospital, Japan who had no disclosures told Medscape Medical News.
Similar views were expressed in 2018 by former Bristol-Myers Squibb investigators Simeon I. Taylor, MD, PhD, an endocrinologist now at the University of Maryland, Baltimore, and nephrologist Bruce R. Leslie, MD, now of Seventh Doctor Consulting, Princeton, New Jersey.
Taylor and Leslie additionally pointout that blood pressures were also imbalanced between the CVOT study arms.
And, Leslie told Medscape Medical News in an interview, those same imbalances as well as in diuretic use also occurred in more recent dedicated trials of the effect of SGLT2 inhibitors on kidney function and heart failure, including CREDENCE and DAPA-HF.
"The imbalance is baked into how these studies are done. Whether intentional or inadvertent, there's an imbalance," asserts Leslie, who owns stock in Bristol-Myers Squibb, Pfizer, and Lilly.
Asked for comment, Silvio Inzucchi, MD, director of the Yale Medicine Diabetes Center, New Haven, Connecticut, and a senior investigator for several of these trials, told Medscape Medical News: "It is extremely difficult to conduct a trial with absolutely equal A1c levels between the treatment groups when you allow an extra drug in one arm."
"So, all of the CVOTs have shown about a 0.4% to 0.7% difference [in A1c] between the groups, sometimes even more depending on the potency of the drug. To have equal A1cs in both groups, the study sites would have to assume complete responsibility for glucose management. That would be a much more complex and much more expensive study...It's also no longer a reflection of 'real-world' practice," he explained.
And in response to similar arguments about the imbalances made in a letter to the New England Journal of Medicine following publication of the renal results of the EMPA-REG Outcome trial with the SGLT2 inhibitor empagliflozin (Jardiance, Lilly/Boehringer Ingelheim),Inzucchi and two other EMPA-REG coauthors called the differences in glycemic and blood pressure control "subtle."
They write, "Treatment with SGLT2 inhibitors results in a reduction in hyperglycemia and blood pressure, and these effects may indeed have contributed to the improved outcome with empagliflozin."
"However, the magnitude and duration of the observed reductions are unlikely to fully account for the positive renal effects...it is more likely that the effects of empagliflozin on reducing intraglomerular hypertension played a more fundamental role than glycemic or hypertension control in mediating the renal effects," they state.
In their article, Shimazawa and Ikeda analyzed results from 12 CVOTs published through December 2018 that followed the FDA's 2008 guidance.
These included three studies of SGLT2 inhibitors (EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58),four of DPP-4 inhibitors (CARMELINA, EXAMINE, SAVOR-TIMI 53, and TECOS),and five of GLP-1 agonists (LEADER, SUSTAIN-6, HARMONY, EXCEL, and ELIXA).
In most of the trials, patients had a high risk of atherosclerotic cardiovascular disease (CVD) or established CVD with baseline A1c levels ranging from 7.2% to 8.7%.
All received active drug or placebo, but they weren't truly "placebo-controlled" trials, as additional glucose-lowering medications were allowed, Shimazawa and Ikeda point out.
There was significantly greater use of additional glucose-lowering drugs in the placebo groups of the 10 trials that reported such data.
But regardless of use of such additional medications, A1c levels were significantly higher in the placebo groups in all the trials, ranging in percentage point difference from 0.27 (in ELIXA) to 1.00 (in SUSTAIN-6).
And despite better glycemic control in the treatment groups, heart failure rates were higher in the treatment groups in EXAMINE and SAVOR-TIMI, leading to warnings regarding this on the labels of two DPP-4 inhibitors.
Ikeda told Medscape Medical News that it shouldn't be difficult to resolve the imbalance problem by adjusting for A1c, as the CVOT investigators "have the critical data of their own, and the post-hoc analyses with adjustment for the imbalance are elementary statistics."
In fact, he noted that this was actually done in one of the CVOTs, ELIXA, resulting in a loss of a significant advantage for lixisenatide in percent change in urinary albumin-to-creatinine ratio (from P = .004 to P = .07).
Leslie is less convinced that the imbalance in glycemic control would have made a major difference in cardiovascular outcomes, at least in the short-term.
"The duration of studies is relatively short. For 3- to 5-year follow-up it seems unlikely that differences in glycemic control can explain the cardiovascular benefit," said Leslie.
However, regarding the CVOTs and other major trials of SGLT2 inhibitors, Leslie said, "My belief is that the difference in outcomes is mostly due to blood pressure difference and diuretic use imbalance, which are intimately related."
He points to evidence including some of his own work that SGLT2 inhibitors have diuretic propertiesand that they enhance the renoprotective effects of reninangiotensinaldosterone system (RAAS) inhibitors by potentiating their antihypertensive and antiproteinuric actions.
Indeed, in a letter to the New England Journal of Medicine following publication of CREDENCE, which showed renal benefit for the SGLT2 inhibitor, Leslie and coauthor Leslie E. Gerwin, JD, of Princeton University, New Jersey, write: "In this trial, canagliflozin a drug with diuretic properties was administered to patients with diabetic kidney disease, nearly all of whom were receiving a [RAAS] inhibitor."
"In the placebo group, however, fewer than half the patients were taking diuretics," they pointout.
There was also a blood pressure imbalance in CREDENCE of 3.30 mmHg (systolic) and 0.95 mmHg (diastolic).
Leslie told Medscape Medical News that the same is true of the CVOTs of SGLT2 inhibitors, including CANVAS, EMPA-REG, and DECLARE TIMI 58, potentially influencing the heart failure outcomes.
"It was the same structure. Less than half of the placebo group was being treated with a diuretic at baseline, but all the treatment group patients got a diuretic [as well as] an SGLT2 inhibitor along with RAAS inhibitors," noted Leslie.
Thus, he said, "all the SGLT2 inhibitor CVOTs, as well as CREDENCE, contain an unbalanced therapeutic design...that leaves unanswered the question of whether the cardiovascular and renal benefits they describe can be reproduced by inexpensive generic thiazide diuretics."
In response to Leslie and Gerwin's letter, CREDENCE lead investigator Meg J. Jardine, MB, PhD, of The George Institute for Global Health, Sydney, Australia, and two coauthors replied: "Diuretics have not been shown to prevent kidney failure."
"The benefits observed in the CREDENCE trial were also consistent, regardless of baseline diuretic use, so we think it is unlikely that the diuretic effect explains the benefits of canagliflozin," they note.
Leslie commented, "Diuretics don't prevent kidney failure, but neither do SGLT2 inhibitors. They just slow it down, same as diuretics."
Inzucchi, who has multiple disclosures relating to the companies conducting these trials, told Medscape Medical News he disagrees with Leslie's assertion that the diuretic effects of SGLT2 inhibitors are the same as those of thiazide diuretics.
"I don't agree that SGLT2 inhibitors are 'just like thiazides.' They work in a totally different part of the nephron, and although they are relatively weak natriuretics, their effect on sodium excretion may be more sustained than with other diuretics," he said.
"This is perhaps because they inhibit sodium reabsorption proximal to the macula densa, so the resultant loss of urinary sodium and subsequent volume contraction does not appear to simulate the normal neurohormonal compensatory mechanisms like conventional diuretics that serve to attenuate efficacy over time. These hormonal changes increases in catecholamines, renin, aldosterone, and antidiuretic hormone may also have deleterious effects on the heart," he explained.
In addition, Inzucchi said, "Thiazides have never been shown to reduce heart failure hospitalizations or mortality as do the SGLT2 inhibitors. So the gliflozins may be unique diuretics."
And in response to another letter expressing concern about the glycemia and blood pressure differences in CREDENCE, Jardine and colleagues write: "Pooled analyses of intensive blood pressure and glucose lowering have not shown clear renal benefits, so these are also unlikely explanations, particularly given the modest differences between the two groups."
"The trial protocol encouraged investigators to deliver the best guideline-based care to patients according to blood pressure and glucose and lipid levels. None of these interventions (ie, the use of diuretics and intensive blood pressure and glucose lowering) has been shown to have benefits of the magnitude observed in the CREDENCE trial, despite multiple trials," they state.
In their letter regarding CREDENCE to the New England Journal of Medicine, Leslie and Gerwin suggesta clinical trial could be conducted comparing canagliflozin added to RAAS inhibition with a generic thiazide diuretic added to RAAS inhibition in patients with diabetic kidney disease and otherwise controlled hyperglycemia.
This, they argue, "could help to determine whether the renoprotective qualities of canagliflozin are anything more than those of an expensive diuretic."
And, as for the CVOTs, Leslie told Medscape Medical News he agrees with the Japanese researchers that post-hoc analyses could provide some answers.
With regard to the diuretic question, the sponsors could address the concern with the data they already have by performing a subanalysis comparing cardiovascular or renal outcomes for patients taking study drug without a concomitant diuretic to the outcomes for patients taking a diuretic and placebo.
"This sort of post-hoc analysis is not as pure as a prespecified one, but at least the data are readily available," said Leslie.
But of course, Leslie and Gerwin also note, the fact that the companies have no incentive to conduct such analyses "exemplifies a deficiency in the pharmaceutical regulatory system."
"Sponsors are not required to ascertain whether the results of [SGLT2 inhibitor] therapy and those of more cost-effective diuretic therapy might be similar," they conclude.
Ikeda has reported no relevant financial relationships. Leslie has reported owning stock in Bristol-Myers Squibb, Pfizer, and Lilly. Inzucchi has reported serving on clinical trial executive/steering/publications committees for AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Sanofi-Lexicon; advisory boards for AstraZeneca, Novo Nordisk, vTv Therapeutics, and Abbott/Alere; and has accepted lecture fees from Boehringer Ingelheim and Merck.
J Pharm Policy Pract. Published online November 18, 2019. Full text
For more diabetes and endocrinology news, follow us on Twitter and Facebook.
See the rest here:
Have the Blockbuster Diabetes Drug Trials Been Biased? - Medscape
- Fresh health warning over common additive used in thousands of ultra-processed foods including mayo and bread - Daily Mail - April 25th, 2024
- Vertex jumps to TreeFrog to enhance production of Type 1 diabetes cell therapy candidates - FiercePharma - April 25th, 2024
- Spotting the warning signs of diabetes in your pets - CBC.ca - April 25th, 2024
- Lexington-Fayette County health department organizing weekend diabetes awareness expo - WEKU - April 25th, 2024
- Preventive effects of SGLT2 inhibitors on incident hypertension in patients with diabetes who do not have hypertension ... - Nature.com - April 25th, 2024
- Curbing the Price of Novel Diabetes and Obesity Medications - Yale School of Medicine - April 25th, 2024
- Stanford Health closing Livermore Diabetes and Bariatric Center - Pleasanton Weekly - April 25th, 2024
- The association of ALT to HDL-C ratio with type 2 diabetes in 5074 years old adults: a population-based study ... - Nature.com - April 25th, 2024
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO ... - PR Newswire - April 25th, 2024
- Understanding the Complexity of Hyperglycemic Emergencies: Exploring the Influence of the Type and Duration of ... - Cureus - April 25th, 2024
- What Every Parent Should Know About Raising a T1D Kid - Health Central - April 25th, 2024
- Healthy Living & Diabetes Awareness Fair 2024 - University of New Mexico - April 25th, 2024
- New findings on pancreatic anatomy may affect diabetes research and treatment - Medical Xpress - April 25th, 2024
- The role of yogurt in diabetes and obesity prevention - News-Medical.Net - April 25th, 2024
- How exercising outdoors can prevent depression and diabetes - inews - April 25th, 2024
- Heart of the Valley: Valley woman discusses how she improved her health following diabetes diagnosis - KRGV - April 25th, 2024
- The Right Amount of Sleep Could Help Prevent This Extremely Common Disease - Inverse - April 25th, 2024
- 'Bread and Butter': Societies Issue T2D Management Guidance - Medscape - April 25th, 2024
- She was fired after not endorsing Splenda-filled salads to people with diabetes. Why? - The Guardian - April 25th, 2024
- Glycemic index of diets: importance beyond diabetes control - The Hindu - April 25th, 2024
- 1 woman thought she was destined for diabetes. This 1 realization helped her lose 70 pounds - Yahoo! Voices - March 29th, 2024
- Franciscan Health offering diabetes education at local churches - The Times of Northwest Indiana - March 29th, 2024
- For diabetes patients, needle-free insulin injections are on the way - ScienceBlog.com - March 29th, 2024
- Las Vegas nonprofit hosting health workshop specifically aimed at local Latinos - KTNV 13 Action News Las Vegas - March 29th, 2024
- How Often Do You Really Need to Check Your Blood Sugar Levels? - WSJ - The Wall Street Journal - March 29th, 2024
- Unintended Effects of Caps on Insulin Out-of-Pocket Costs - Managed Healthcare Executive - March 29th, 2024
- Study: Pompe treatment Nexviazyme isn't linked to new or worsening... - Pompe Disease News - March 29th, 2024
- A Smoker With New-Onset Pain in Both Feet - Medscape Reference - March 29th, 2024
- Pre-diabetes leads to Type 2 diabetes; Here's how to prevent and reverse it - WXII12 Winston-Salem - March 29th, 2024
- 'From Interpretation to Action': Using CGM to Manage T2D - Medscape - March 29th, 2024
- March: diabetes-kidney | News and features - University of Bristol - March 29th, 2024
- Health centers attempt to prevent diabetes - WTVM - March 29th, 2024
- Beyond Meat Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart ... - Yahoo Finance - March 29th, 2024
- Beyond Meat Launches Revamped Plant-Based Crumbles, Earning American Heart and Diabetes Association ... - vegconomist - the vegan business magazine - March 29th, 2024
- Ypsomed hands off insulin pen needle business to focus on smart pump, autoinjector development - Fierce Biotech - March 29th, 2024
- Take the online diabetes test that could help save your life - NBC Connecticut - March 29th, 2024
- Study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes - News-Medical.Net - March 29th, 2024
- Risk prediction using genes and gut bacteria can improve early detection of diseases like type 2 diabetes - Medical Xpress - March 29th, 2024
- On a Healthy Vegan Diet, I've Healed My Liver, Reversed Type 2 Diabetes, and Lost 35 Pounds - Forks Over Knives - March 29th, 2024
- Study Links Diet, Diabetes, and Alzheimers - Neuroscience News - March 29th, 2024
- Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be - Yahoo Finance - March 18th, 2024
- Doctor warns of strange telltale sign of diabetes which can appear on the legs - The Mirror - March 18th, 2024
- Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies - News-Medical.Net - March 18th, 2024
- Popular diabetes and weight loss drugs often hard to get for people who need them - NBC News - March 18th, 2024
- Your Health Matters: The ABCs of diabetes - The Globe | News, weather, sports from Worthington, Minnesota - The Globe - March 18th, 2024
- The Link Between Pancreatic Cancer and Diabetes - Cedars-Sinai - March 18th, 2024
- Nikita Kuzmin diabetes: what was he holding in the CBB house? - Cosmopolitan UK - March 18th, 2024
- FDA Approves Rezdiffra, the First Drug for Diabetes-Related Liver Disease - diaTribe Foundation - March 18th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Can Eating Yogurt Really Reduce Your Risk of Diabetes? - Health.com - March 18th, 2024
- Even short periods of diabetes remission are linked to lower risk of heart attack and stroke - The BMJ - March 18th, 2024
- Kidney stone risk factors and how type 2 diabetes medication may help - WECT - March 18th, 2024
- 'Making the Invisible Visible': CGMs Offer Insights for T2D - Medscape - March 18th, 2024
- Novo Nordisk Discontinues Insulin Medication After Cutting Its Price - The American Prospect - March 18th, 2024
- Infographic: Where GLP-1s Work Now -- and What's Coming - Medscape - March 18th, 2024
- Intermountain Health Experts Say Education Key to Prevention of Type 2 Diabetes | PRUnderground - PR Underground - March 18th, 2024
- International body recommends more sensitive test to indicate risk of developing diabetes - The Hindu - March 18th, 2024
- The importance of knowing your A1C level - KSAT San Antonio - March 18th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Business Wire - January 9th, 2024
- Diffuse Alveolar Hemorrhage Occurring Suddenly in a Diabetic Patient With Asthma Exacerbation - Cureus - January 9th, 2024
- Virginia Tech researchers find drugs used to treat Type 2 diabetes reduce alcohol cravings - WRIC ABC 8News - January 9th, 2024
- FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss - CNN - January 9th, 2024
- Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to ... - Cardiovascular Diabetology - January 9th, 2024
- Insulin price cap: More Americans will now pay no more than $35 - USA TODAY - January 9th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- No Increased Risk of Suicidal Ideation With GLP-1 Drugs - Medpage Today - January 9th, 2024
- Ask the Doctors | New research being conducted to treat diabetes - Eureka Times-Standard - January 9th, 2024
- Salivary Chloride Intracellular Channel 1 (CLIC1) as a Hub of Gene-Gene Interactome of Periodontitis With Diabetes ... - Cureus - January 9th, 2024
- Why Omada's CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program - MedCity News - January 9th, 2024
- Researchers find drugs used to treat type 2 diabetes and obesity reduce alcohol cravings - Medical Xpress - January 9th, 2024
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different ... - Nature.com - January 9th, 2024
- CV Safety Profile of TheracosBio's BRENZAVVY (bexagliflozin) Confirmed in Research Published in Diabetes ... - Business Wire - January 9th, 2024
- 6 "Bad" Fruits You Should Be Eating When You Have Diabetes, According to Dietitians - EatingWell - January 9th, 2024
- Children of Women with Type 1 Diabetes Have Increased Heart Defect Risk - Inside Precision Medicine - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- Ozempic and weight loss | News and views - Diabetes UK - January 9th, 2024
- Drugs used to treat Type 2 diabetes reduce alcohol cravings - ScienceBlog.com - January 9th, 2024
- People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds - ABC News - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023